BRPI0416501A - forma de dosagem farmacêutica com múltiplas camadas contendo uma substáncia que age de uma forma modulatória, no que diz respeito á liberação das substáncias ativas - Google Patents

forma de dosagem farmacêutica com múltiplas camadas contendo uma substáncia que age de uma forma modulatória, no que diz respeito á liberação das substáncias ativas

Info

Publication number
BRPI0416501A
BRPI0416501A BRPI0416501-2A BRPI0416501A BRPI0416501A BR PI0416501 A BRPI0416501 A BR PI0416501A BR PI0416501 A BRPI0416501 A BR PI0416501A BR PI0416501 A BRPI0416501 A BR PI0416501A
Authority
BR
Brazil
Prior art keywords
substance
release
sub
optionally
active substances
Prior art date
Application number
BRPI0416501-2A
Other languages
English (en)
Inventor
Rosario Lizio
Hans-Ulrich Petereit
Manfred Assmus
Hema Ravishankar
Original Assignee
Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roehm Gmbh filed Critical Roehm Gmbh
Publication of BRPI0416501A publication Critical patent/BRPI0416501A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMA DE DOSAGEM FARMACêUTICA COM MúLTIPLAS CAMADAS CONTENDO UMA SUBSTáNCIA QUE AGE DE UMA FORMA MODULATóRIA, NO QUE DIZ RESPEITO à LIBERAçãO DAS SUBSTáNCIAS ATIVAS". A presente invenção refere-se a uma forma de dosagem farmacêutica com múltiplas camadas para a liberação controlada de substâncias ativas, contendo: a) uma camada nuclear, compreendendo uma substância que age de uma forma modulatória em consideração à liberação de substâncias ativas, opcionalmente um núcleo neutro e/ou uma substância ativa; b) uma camada de controle interna que influencia a liberação da substância que age de uma forma modulatória e da substância ativa opcionalmente contida da camada nuclear, contendo polímeros, ceras, resinas e/ou proteínas farmaceuticamente usáveis; c) uma camada de substância ativa contendo uma substância farmaceuticamente ativa e, opcionalmente, uma substância que age de uma forma modulatória; d) uma camada de controle externa contendo um copolímero de (met)acrilato ou uma mistura consistindo em uma variedade de copolímeros de (met)acrilato compreendidos de 98 a 85 ésteres de alquila C~ 1-C~ 4~ do ácido (met)acrílico e 2 a 15% em peso de monómeros de metacrilato com um grupo de amónio quaternário no radical alquila e opcionalmente contendo polímeros farmaceuticamente usáveis que são insolúveis em água, por meio do qual as camadas podem conter, em adição e de uma forma conhecida, adjuvantes farmaceuticamente convencionais.
BRPI0416501-2A 2003-11-13 2004-09-15 forma de dosagem farmacêutica com múltiplas camadas contendo uma substáncia que age de uma forma modulatória, no que diz respeito á liberação das substáncias ativas BRPI0416501A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353186A DE10353186A1 (de) 2003-11-13 2003-11-13 Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
PCT/EP2004/010297 WO2005046649A2 (de) 2003-11-13 2004-09-15 Mehrschichtige arzneiform, enthaltend eine in bezug auf die wirkstoffreigabe modularisch wirkende substanz

Publications (1)

Publication Number Publication Date
BRPI0416501A true BRPI0416501A (pt) 2007-01-09

Family

ID=34585088

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416501-2A BRPI0416501A (pt) 2003-11-13 2004-09-15 forma de dosagem farmacêutica com múltiplas camadas contendo uma substáncia que age de uma forma modulatória, no que diz respeito á liberação das substáncias ativas

Country Status (15)

Country Link
US (1) US20060269605A1 (pt)
EP (1) EP1684729B1 (pt)
JP (1) JP2007510676A (pt)
KR (1) KR20060121182A (pt)
CN (1) CN1863515A (pt)
AT (1) ATE395046T1 (pt)
BR (1) BRPI0416501A (pt)
CA (1) CA2544497A1 (pt)
DE (2) DE10353186A1 (pt)
ES (1) ES2307044T3 (pt)
IL (1) IL175561A0 (pt)
MX (1) MX2007010611A (pt)
PL (1) PL1684729T3 (pt)
SI (1) SI1684729T1 (pt)
WO (1) WO2005046649A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
KR20070119658A (ko) * 2005-03-29 2007-12-20 에보니크 룀 게엠베하 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태
KR101413613B1 (ko) * 2006-01-27 2014-07-10 앱탈리스 파마테크, 인코포레이티드 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템
JP2009526096A (ja) * 2006-02-07 2009-07-16 エフ エム シー コーポレーション 徐放性被覆をつくるためのコーティング方法
WO2007092717A1 (en) * 2006-02-07 2007-08-16 Fmc Corporation Latex or pseudolatex compositions coatings and coating processes
KR20080099334A (ko) * 2006-02-24 2008-11-12 테바 파마슈티컬 인더스트리즈 리미티드 메토프로롤 숙시네이트 서방정 및 이의 제조 방법
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009086942A1 (en) * 2008-01-10 2009-07-16 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
SI2230932T1 (sl) * 2008-01-10 2017-07-31 Evonik Roehm Gmbh Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
MX2010007579A (es) * 2008-01-10 2010-08-03 Evonik Roehm Gmbh Preparacion nutriceutica o farmaceutica revestida con una liberacion de sustancia activa de impulsion mejorada.
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
WO2011025969A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission
ES2508490T3 (es) * 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
US8980318B2 (en) 2010-06-24 2015-03-17 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
KR20130124551A (ko) 2011-02-02 2013-11-14 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
WO2012137610A1 (ja) * 2011-04-08 2012-10-11 国立大学法人山梨大学 医薬製剤
BR112014004370A2 (pt) * 2011-08-26 2017-03-21 Wockhardt Ltd métodos para tratar distúrbios cardiovasculares
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제
KR101451327B1 (ko) 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
CN103637999B (zh) * 2013-12-12 2014-12-03 南通联亚药业有限公司 一种多层固体药物剂型
WO2016044704A1 (en) 2014-09-19 2016-03-24 The Procter & Gamble Company Pulsed release phenylephrine dosage forms
TWI525110B (zh) 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
DK3648743T3 (da) * 2017-07-07 2022-10-03 Dsm Ip Assets Bv Pressede tabletter, der omfatter nitrooxyforbindelser
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN114159400A (zh) * 2021-11-22 2022-03-11 山东省药学科学院 法匹拉韦包芯片

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426230B2 (ja) * 1991-05-20 2003-07-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド 複数層の制御放出処方剤
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
DE19956486A1 (de) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Mehrschichtige Zubereitung zur gesteuerten, pulsartigen Abgabe von Wirkstoffen
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform

Also Published As

Publication number Publication date
SI1684729T1 (sl) 2008-10-31
DE10353186A1 (de) 2005-06-16
JP2007510676A (ja) 2007-04-26
ES2307044T3 (es) 2008-11-16
ATE395046T1 (de) 2008-05-15
EP1684729A2 (de) 2006-08-02
US20060269605A1 (en) 2006-11-30
CN1863515A (zh) 2006-11-15
CA2544497A1 (en) 2005-05-26
KR20060121182A (ko) 2006-11-28
IL175561A0 (en) 2006-09-05
DE502004007172D1 (de) 2008-06-26
MX2007010611A (es) 2009-02-19
WO2005046649A3 (de) 2005-10-27
EP1684729B1 (de) 2008-05-14
WO2005046649A2 (de) 2005-05-26
PL1684729T3 (pl) 2008-10-31

Similar Documents

Publication Publication Date Title
BRPI0416501A (pt) forma de dosagem farmacêutica com múltiplas camadas contendo uma substáncia que age de uma forma modulatória, no que diz respeito á liberação das substáncias ativas
WO2005046561A3 (de) Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix
AU2003266351A1 (en) Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers
WO2000019984A3 (de) Überzogene arzneiformen mit kontrollierter wirkstoffabgabe
BRPI0621996B8 (pt) preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
WO2006010394A3 (de) Mehrschichtige arzneiform
WO2006102964A3 (en) Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
DE502005006022D1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
MX2013014142A (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
WO2004017922A3 (en) Keto cannabinoids with therapeutic indications
ATE442250T1 (de) Thermoformbare verpackungsfolien
WO2009038082A1 (ja) 感光性樹脂組成物及びその積層体
ATE273333T1 (de) (co-)polymerisate von hydroxyalkyl(meth)acrylaten,verfahren zu deren herstellung sowie deren verwendung in pharmazeutischen darreichungsformen
Bannwarth et al. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor
BRPI0822140A8 (pt) Preparação farmacêutica ou nutracêutica revestida tendo liberação pulsada de subsatância ativa
Azimi et al. Effects of peripheral and intra-hippocampal administration of sodium salicylate on spatial learning and memory of rats
BR112021017735A2 (pt) Forma de dosagem que compreende uma matriz polimérica
Lovegrove moved to London in 1880 McKilliam himself entered the movement. The lay spirit of the awakenings has perhaps been underestimated in histories of the Brethren as an important shaping force on its ethos. After 1859 the movement to some extent was remade, with Brethrenism inheriting not only the anti-establishment spirit of mid-century revivalism, but also its lay orientation. The upsurge in lay activity was an important part of the evangelicalism from which Brethrenism emerged and tensions between clerical establish-ments and laypeople became a significant cause of accessions to the new movement. The Brethren developed their own thinking on the laity, but their principles and practices did not arrive fully fledged. The commemoration of the Lord’s supper in Dublin to which Brethren origins are traced, initially had a set order of service, but it gradually came to allow spontaneous participa-tion by attendants. The mature thought of Darby, in particular, slowly
SU683733A1 (ru) Материал дл изготовлени зубных протезов
Meier et al. Long‐term efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia
TH32363A (th) สารผสมสำหรับการดูแลรักษาส่วนบุคคล
Kamphuis et al. Renal terminology
RU2004130744A (ru) Способ формирования повышенной судорожной готовности (киндлинга) у мышей

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.